By linking the function of ADAM9 to clinically relevant outcomes in lung cancer patients, we have demonstrated that ADAM9 could be useful as both a prognostic biomarker and as a molecular target for reducing cancer progression. This evidence concerns the gene ADAM9 and lung carcinoma.